Anti-Human Galectin-9 Reference Antibody (HFB200901, RUO) (HT173036)

Name: Anti-Human Galectin-9 Reference Antibody (HFB200901, RUO)
Brand: abinScience
SKU: HT173036
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HT173036
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	HFB200901
Activité biologique	Anti-LGALS9 (HFB200901) (10 ug/mL; 1 h) potently inhibits rLGALS9-induced vacuolization in MDCK and DLD-1 KRAS G12C mutant colon carcinoma cells [1]. HFB200901 (20 ug-10 mg; s.c.; once weekly; 8 weeks) reduces pancreatic LGALS9 expression, lowers peripheral and infiltrating Treg levels, increases pancreatic-infiltrating CD4 + T cells, and limits PanIN progression in KC mice [2].
Système d'expression	Mammalian cells
Cible	Ecalectin, LGALS9, Galectin-9, Gal-9, Tumor antigen HOM-HD-21
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	O00182
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	HFB200901
Contexte	Galectin-9 (Gal-9) is a ~39 kDa protein. Binds galactosides. Has high affinity for the Forssman pentasaccharide. Ligand for HAVCR2/TIM3. Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death. Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth. 1. Nagae, M. et al. (2008) Journal of molecular biology 375, 119-35. PMID: 18005988 2. Zhu, C. et al. (2005) Nature immunology 6, 1245-52. PMID: 16286920 3. Bi, S. et al. (2011) Proceedings of the National Academy of Sciences of the United States of America 108, 10650-5. PMID: 21670307 4. Gieseke, F. et al. (2013) European journal of immunology 43, 2741-9. PMID: 23817958 5. Mengshol, JA. et al. (2010) PloS one 5, e9504. PMID: 20209097 6. Dai, SY. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 2974-81. PMID: 16116184 7. Kojima, R. et al. (2014) PloS one 9, e86106. PMID: 24465902 9. Golden-Mason, L. et al. (2013) Journal of virology 87, 4835-45. PMID: 23408620
Reférences	1. Wiersma VR, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy. 2015;11(8):1373-1388. [HT173036] 2. Quilbe A, et al. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice. Front Immunol. 2023;14:1267279. Published 2023 Nov 30. [HT173036] 3. Pranjol M Z I, Zinovkin D A, Potapnev M P. The role of galectins in the immune microenvironment in human cancers and potential therapeutic approaches[J]. Frontiers in Immunology, 2024, 15: 1448407. [HT173036] 4. Lu B, et al. LGALS9 blockade augments vaccine-induced immune responses against prostate cancer. J Immunother Cancer. 2026;14(5):e014141. Published 2026 May 8. View More [HT173036]
Note	For research use only. Not suitable for clinical or therapeutic use.